A 52-year-old man with acute myocardial infarction and cardiogenic shock (SBP 85 mmHg, HR 105/min, CI 1.8 L/min/m², PCWP 22 mmHg) is on dobutamine 5 mcg/kg/min. Despite this, cardiac index remains low and systemic hypotension worsens. What is the most appropriate next step?

Explanation

## Clinical Context: Cardiogenic Shock with Inotropic Failure This patient has cardiogenic shock (low cardiac index, elevated PCWP, hypotension) on monotherapy with dobutamine. The worsening hypotension despite inotropic support indicates **distributive component** (systemic vasodilation from dobutamine's β₂-mediated vasodilation) superimposed on cardiogenic shock. ## Pathophysiology of Dobutamine-Induced Hypotension **Key Point:** Dobutamine is a selective β₁-agonist with some β₂ activity. At higher doses, β₂-mediated vasodilation predominates, causing systemic hypotension that paradoxically worsens coronary perfusion pressure and cardiac output. **High-Yield:** In cardiogenic shock unresponsive to inotropes alone, combination therapy with an inotrope (β₁-agonist) + vasopressor (α₁-agonist) is superior to either agent alone. ## Adrenergic Receptor Profile & Clinical Effects | Agent | α₁ | β₁ | β₂ | Effect on BP | Effect on HR | Clinical Use | |-------|-----|-----|-----|---|---|---| | **Dobutamine** | — | +++ | ++ | ↓ (vasodilation) | ↑↑ (tachycardia) | Inotrope; causes hypotension | | **Noradrenaline** | +++ | ++ | + | ↑↑ (vasoconstriction) | ↑ (mild) | Vasopressor; restores perfusion | | Milrinone | — | — | — | ↓ (PDE3 inhibitor) | ↑ | Inodilator; worsens hypotension | | Adrenaline | +++ | +++ | +++ | ↑ (dose-dependent) | ↑↑ | Reserved for refractory shock | ## Rationale for Combination Therapy **Clinical Pearl:** Adding a vasopressor (noradrenaline) to an inotrope (dobutamine) achieves: 1. **Inotropy** from dobutamine (β₁ effect) 2. **Vasoconstriction** from noradrenaline (α₁ effect) → restores systemic vascular resistance and perfusion pressure 3. **Synergistic improvement** in cardiac output and blood pressure This is the standard approach in cardiogenic shock refractory to single-agent inotropic therapy. ## Why Escalating Dobutamine Fails Increasing dobutamine dose amplifies β₂-mediated vasodilation, worsening hypotension and reducing coronary perfusion pressure — a counterproductive spiral in cardiogenic shock. **Warning:** Do not escalate a single inotrope when hypotension develops; add a vasopressor instead.